Establishment and characterization of cell lines derived from uterine malignant mixed Müllerian tumor.
暂无分享,去创建一个
W. H. Kim | H. Park | J. Chung | J. G. Park | H S Park | J G Park | H. Han | J. H. Lee | S. Kang | W H Kim | J K Chung | Y Yuan | H S Han | J H Lee | S B Kang | Y. Yuan | W. H. Kim | S. Kang
[1] R. Bast,et al. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. , 1994 .
[2] W B OBER,et al. UTERINE SARCOMAS: HISTOGENESIS AND TAXONOMY , 1959 .
[3] Y. Kaneko,et al. Two cell lines established from mixed Müllerian tumors of the uterus morphologic, immunocytochemical, and cytogenetic analyses , 1992, Cancer.
[4] R. Ian Freshney,et al. Culture of Animal Cells , 1983 .
[5] H. Iwasaki,et al. Characteristics of cloned cells of mixed müllerian tumor of the human uterus carcinoma cells showing myogenic differentiation in vitro , 1993, Cancer.
[6] M. Williamson,et al. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. , 1995, Human molecular genetics.
[7] J. Sambrook,et al. Molecular Cloning: A Laboratory Manual , 2001 .
[8] K. Geisinger,et al. Malignant mixed müllerian tumors an ultrastructural and immunohistochemical analysis with histogenetic considerations , 1987, Cancer.
[9] B. Scheithauer,et al. Clinicopathologic analysis of uterine malignant mixed müllerian tumors. , 1989, Gynecologic oncology.
[10] T. Sekiya,et al. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. , 1989, Genomics.
[11] A. Gown,et al. The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma. , 1996, Gynecologic oncology.
[12] E. O. Williamson,et al. Malignant mixed müllerian tumors of the uterus , 1972, Cancer.
[13] Y. Shimosato,et al. EXPRESSION OF VARIOUS ANTIGENS BY DIFFERENT COMPONENTS OF UTERINE MIXED MÜLLERIAN TUMORS: An Immunohistochemical Study , 1988, Acta pathologica japonica.
[14] A. Gazdar,et al. CHARACTERISTICS OF COLORECTAL CARCINOMA CELL LINES paraffin embedded sections of xenografts , 2006 .
[15] I. Ishiwata,et al. Establishment and characterization of two human mixed mesodermal tumor cell lines from the same patient. , 1984, Journal of the National Cancer Institute.
[16] Y. Nakamura,et al. Germline mutations of hMLH1 and hMSH2 genes in Korean hereditary nonpolyposis colorectal cancer. , 1996, Journal of the National Cancer Institute.
[17] T. Sekiya,et al. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[18] B. Sikic,et al. Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drugs. , 1983, Cancer research.
[19] F. Collins,et al. Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.
[20] J. Boyd,et al. Mutation and over‐expression of the P53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas , 1994, Obstetrics and gynecology.
[21] G. Fletcher,et al. Malignant mixed müllerian tumors of the uterus , 1984, Cancer.
[22] H. Taylor,et al. Mesenchymal tumors of the uterus: III. A clinical and pathologic study of 31 carcinosarcomas , 1966 .
[23] C. Harris,et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.
[24] Y. Nakamura,et al. Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer. , 1993, Cancer research.
[25] E. M. Gilder,et al. Handbuch der speziellen pathologischen Anatomie und Histologie , 1972 .
[26] M. Feldstein,et al. Uterine sarcomas. Natural history, treatment and prognosis , 1978, Cancer.
[27] J. Minna,et al. Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. , 1986, Cancer research.
[28] H. Taylor,et al. Mesenchymal tumors of the uterus. II. A clinical and pathologic study of 31 mixed mesodermal tumors. , 1966, Obstetrics and gynecology.
[29] Graham Jb,et al. Carcinosarcoma and mixed mesodermal tumor of the uterine corpus. Review of 49 cases. , 1970 .
[30] K. Shroyer,et al. Alteration of the p53 tumor suppressor gene and activation of c-K-ras-2 protooncogene in endometrial adenocarcinoma from Colorado. , 1995, American journal of clinical pathology.
[31] M. Kelley,et al. Mutation of p53 gene in hepatocellular carcinoma cell lines with HBX DNA , 1996, International Journal of Cancer.
[32] K. Klaamas,et al. IgG immune response to Helicobacter pylori antigens in patients with gastric cancer as defined by ELISA and immunoblotting , 1996, International journal of cancer.
[33] H. Ishikawa,et al. Histogenesis and culture of human uterine carcinosarcoma. , 1981, Cancer research.
[34] Steven E. Bayer,et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.
[35] R. White,et al. Microsatellite instability in colorectal adenocarcinoma cell lines that have full-length adenomatous polyposis coli protein. , 1995, Cancer research.
[36] R. Kempson,et al. Uterine sarcomas: Classification, diagnosis, and prognosis , 1970 .
[37] F. Sanger,et al. DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.
[38] J. Goding,et al. Monoclonal Antibodies: Principles and Practice , 1996 .
[39] H. Minaguchi,et al. Establishment and characterization of carcinosarcoma cell line of the human uterus , 1993, Cancer.